Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachA defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosisFingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsPonesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseasesLysophospholipids and their receptors in the central nervous systemFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapySphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyondFingolimod for the treatment of neurological diseases-state of play and future perspectivesThe Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisExpression of LPP3 in Bergmann glia is required for proper cerebellar sphingosine-1-phosphate metabolism/signaling and developmentTherapeutic decisions in multiple sclerosis: moving beyond efficacyCurrent and emerging therapies in multiple sclerosis: a systematic reviewActive, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal NeuronsAutoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development.Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MSTargeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.Myelin recovery in multiple sclerosis: the challenge of remyelinationMechanism of action of oral fingolimod (FTY720) in multiple sclerosis.FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.Fingolimod and cardiac risk: latest findings and clinical implicationsFTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.Fingolimod for relapsing multiple sclerosis: an update.FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons.Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.Fingolimod modulates microglial activation to augment markers of remyelination.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic moleculesS1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisInduction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastomaOral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.Fingolimod effects in neuroinflammation: Regulation of astroglial glutamate transporters?
P2860
Q22305854-613DCE5E-9F84-45F3-878A-CF6B5A60905DQ24644684-C9F1F8E9-9A70-474F-8778-D7ED2608FCB5Q26765300-062FD2DB-453D-4F25-9870-8A2DB61AFDC0Q26771821-4D8A14DE-AEE1-4908-B4C6-E48B7B1F7BDFQ26859168-1F57D0B6-B9A3-4C87-ADE3-D7AF42AB9B6EQ27011473-5D19E2B1-EE68-4F6A-A86D-BA35EBA6460DQ27011857-FF3D0B4D-5115-4266-B194-34B30DB7B214Q27026175-7573C6FD-F378-45F3-BF0E-C34970B2AD62Q28073377-15E861DE-6397-427A-AB56-FC4A3D559647Q28508004-86CED464-9D00-4FEF-B626-D64BA6018DC0Q28541039-2DAAFC52-6C77-449B-88A6-ABA4854EE45CQ29010983-277E460E-A1D6-4FA7-8841-D98472D6F009Q30605352-D0C93954-9D06-45BF-9AE1-848287A41431Q30836800-125B235F-023D-455B-8B1D-3EFABFEB55A0Q30890487-59356CE6-8ACC-4F27-941D-DCDB294CFDD5Q33598597-A336A298-B8E0-4F19-B442-0D9F1C7F2490Q33651898-686FF199-B1F9-4EE4-972B-67E4C4BB8FB4Q33772195-CA171E72-A70E-4462-AB31-C6E8DB2CA9C7Q33810559-C23909C8-DC1B-41CE-B1BB-9EDADF8443CDQ33854428-1D241B22-3619-410A-9327-170D4AED12B1Q33881977-2A7915BC-B9E6-4563-A321-CE41BF9C8918Q33882403-02E70A4B-24C2-4BFC-931D-E3C3556697BEQ33947251-297904EB-5BE0-49D9-BB0B-1361B63E78EAQ33949504-DCB91576-BC02-48AB-843C-DB9FA9B3BAB0Q34490581-49CCEA52-ACA8-45F1-B7E5-C83673F43799Q34618474-B37BE4D0-6692-4A26-BC4A-56C90E076D47Q34718530-AC8E7537-5D5F-4F70-B14A-CA80CDBBEBB4Q34729032-E258718D-1B8A-4667-A2CF-241522E3125BQ34813347-4EF73466-600C-4700-8513-CF2D62875E54Q35130512-C099CF06-D19F-47B7-B55E-090C4F6ECBCFQ35154946-DCC37621-1616-4249-B4F6-CCEB20EBAB14Q35551835-10A2D249-8122-4B99-A0AF-9DD1E6580718Q35589934-D5B48A07-6DDD-4400-9908-F7ECB77C083EQ35684358-18B8A4BF-5D7F-4DE3-B19F-C998F8AC6B85Q35688505-80E57775-659F-44A9-ADB5-1B1C49F20A77Q35826151-1C29833C-1259-4A87-A383-59BA8FDCACCEQ35845241-F058B85B-DE6F-4433-AFE4-F06A76E6A1D7Q35853209-EFFAD1EA-1BC4-4900-9B76-7D07240DBE34Q36212795-531000D3-7DC3-48BA-A577-9C0CF3EF25CAQ36300679-41C47103-67D1-4D29-86B9-204BD9DD8B31
P2860
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Brain penetration of the oral ...... action in multiple sclerosis.
@ast
Brain penetration of the oral ...... action in multiple sclerosis.
@en
Brain penetration of the oral ...... action in multiple sclerosis.
@nl
type
label
Brain penetration of the oral ...... action in multiple sclerosis.
@ast
Brain penetration of the oral ...... action in multiple sclerosis.
@en
Brain penetration of the oral ...... action in multiple sclerosis.
@nl
prefLabel
Brain penetration of the oral ...... action in multiple sclerosis.
@ast
Brain penetration of the oral ...... action in multiple sclerosis.
@en
Brain penetration of the oral ...... action in multiple sclerosis.
@nl
P2093
P921
P356
P1476
Brain penetration of the oral ...... action in multiple sclerosis.
@en
P2093
Alain Schweitzer
Andreas Billich
Balázs Balatoni
Carolyn A Foster
Christian Beerli
Elke Persohn
Laurence M Howard
Manuela Schwartz
Peter C Hiestand
Roland Reuschel
P304
P356
10.1124/JPET.107.127183
P407
P577
2007-08-06T00:00:00Z